RT Journal Article
SR Electronic
T1 Timing and Predictors of Tuberculosis Incidence among Contacts
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.02.24316631
DO 10.1101/2024.11.02.24316631
A1 Asare-Baah, Michael
A1 Lauzardo, Michael
A1 Johnston, Lori
A1 Dominique, Lina
A1 Séraphin, Marie Nancy
YR 2024
UL http://medrxiv.org/content/early/2024/11/04/2024.11.02.24316631.abstract
AB Contact investigations are crucial for tuberculosis (TB) control, yet the temporal dynamics of disease progression among exposed contacts remain poorly understood. Here, we analyzed a retrospective cohort of 44,106 contacts of 6,243 TB cases identified through the Florida Department of Health surveillance system (2009-2023). During the 15-year follow-up period, 454 individuals within this cohort developed active TB disease. Using survival analysis and mixed-effect Cox proportional hazards models, we determined that the median time to TB disease onset was 11 months following the initial contact investigation. The risk of progression to TB disease varied markedly by age and immune status. Children aged 0-5 years showed nearly seven times higher risk of TB disease progression compared to adults 65 years and older (aHR = 6.66, 95% CI: 1.33-33.27). HIV-positive contacts demonstrated a five-fold increased risk (aHR = 4.75, 95% CI: 2.43-9.30) relative to HIV-negative individuals. These findings indicate that the risk of TB transmission and disease progression persists beyond initial contact investigation activities and varies significantly across demographic and clinical subgroups, suggesting the need for extended contact monitoring and age-specific preventive strategies, particularly for young children and immunocompromised individuals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study received approval from the Institutional Review Board (IRB) at the University of Florida (approval number IRB201700445) and the Florida Department of Health (FDOH) TB Program. It was conducted as part of program evaluations and projects aimed at improving the clinical and public health services offered by state and local TB programs in Florida (SOW21-473 6.1.11). The approval authorities waived the requirement for informed consent, as the research used existing records and did not involve direct interaction with participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableThe dataset analyzed in this study includes sensitive patient information extracted from the Report of the Verified Case of Tuberculosis form. To protect patient privacy and maintain confidentiality, this dataset cannot be made publicly available. However, qualified researchers may access the dataset upon reasonable request, provided they adhere to appropriate data use agreements with the relevant institutional authorities that oversee the protection of this information thus the Institutional Review Board (IRB) at the Florida Department of Health (FDOH) TB Program.